This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Reunion Neuroscience Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Greg Mayes

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	n/a
Management average tenure	less than a year
Board average tenure	3.3yrs

Recent management updates

Recent updates

CEO

Greg Mayes (54 yo)

less than a year

Tenure

Mr. Gregory T. Mayes, also known as Greg, Esq., J.D., is President and Chief Executive Officer of Reunion Neuroscience Inc. from September 2022 and serves as its Director since October 07, 2022. He served...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Hannan Fleiman	Co-Founder & Non-Independent Director	no data	CA$282.64k	6.11% $ 762.1k
Nathan Bryson	Chief Science Officer	3.3yrs	CA$411.37k	0.010% $ 1.2k
Gregory Mayes	President	less than a year	no data	no data
Edward Smith	Chief Financial Officer	less than a year	no data	no data
Curtis Weber	General Counsel	less than a year	no data	0.55% $ 68.8k
Stephan Cote	Head of Quality	1.7yrs	no data	0.0068% $ 851.6
Robert Alexander	Chief Medical Officer & Senior Advisor	less than a year	no data	no data

0.9yrs

Average Tenure

53yo

Average Age

Experienced Management: REUN's management team is not considered experienced ( 0.9 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Hannan Fleiman	Co-Founder & Non-Independent Director	4.3yrs	CA$282.64k	6.11% $ 762.1k
Gregory Mayes	President	less than a year	no data	no data
Robert Alexander	Chief Medical Officer & Senior Advisor	no data	no data	no data
Barry Fishman	Independent Lead Director	2.2yrs	CA$676.69k	0.26% $ 31.9k
Michael Ehlers	Advisor	no data	no data	no data
Sidney Kennedy	Member of Medical Advisory Board	no data	no data	no data
Helen Boudreau	Independent Director	3.3yrs	CA$97.62k	no data
Dieter Weinand	Independent Director	3.3yrs	CA$65.08k	no data
Joseph del Moral	Chairman of the Board	4.3yrs	CA$282.64k	9.58% $ 1.2m
Barry Waisglass	Member of Medical Advisory Board	no data	no data	no data
John Hanlon	Member of Medical Advisory Board	no data	no data	no data
Robert McMaster	Member of Medical Advisory Board	no data	no data	no data

3.3yrs

Average Tenure

54yo

Average Age

Experienced Board: REUN's board of directors are considered experienced (3.3 years average tenure).

This company has been acquired

Reunion Neuroscience Management

Management criteria checks 1/4

Key information

Recent management updates

Reunion Neuroscience Inc., Annual General Meeting, Jul 12, 2023

Reunion Neuroscience Appoints Robert Alexander as Chief Medical Officer

High number of new directors

High number of new and inexperienced directors

Reunion Neuroscience Inc. Appoints Edward Smith as Chief Financial Officer

Reunion Neuroscience Inc. Appoints Edward Smith as Chief Financial Officer

Recent updates

Reunion Neuroscience Inc. Announces First Patient Dosed in Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum Depression

Reunion Neuroscience Inc. announced that it has received CAD 103 million in funding from a group of investors

Reunion Neuroscience Inc. Announces FDA Clearance of IND Application to Initiate A Phase 2 Study of Re104 for the Treatment of Postpartum Depression

Reunion Neuroscience Inc. Files Form 15

MPM Asset Management, L.L.C. acquired Reunion Neuroscience Inc. (TSX:REUN) in a going private transaction.

Reunion Neuroscience's Shares to Be De-Listed from the Toronto Stock Exchange on the Close of Markets on or Around August 2, 2023

New major risk - Financial position

MPM Asset Management, L.L.C. entered into a definitive arrangement agreement to acquire Reunion Neuroscience Inc. (TSX:REUN) for CAD 17.7 million in a going private transaction.

Reunion Neuroscience Inc., Annual General Meeting, Jul 12, 2023

Reunion Neuroscience Inc. to Report Q3, 2023 Results on Feb 14, 2023

Reunion Neuroscience Appoints Robert Alexander as Chief Medical Officer

Reunion Neuroscience Inc. Completes Interim Data Analysis for Phase 1 Clinical Trial with Novel Serotonergic Psychedelic Re104

High number of new directors

Reunion Neuroscience Inc. to Report Q2, 2023 Results on Nov 14, 2022

High number of new and inexperienced directors

Reunion Neuroscience Inc. Appoints Edward Smith as Chief Financial Officer

Reunion Neuroscience Inc. Appoints Edward Smith as Chief Financial Officer

Reunion Neuroscience Inc. Announces Executive Changes

Reunion Neuroscience announces resignation of director, general counsel

Reunion Neuroscience Inc. Appoints Greg Mayes as President

Reunion Neuroscience appoints Greg Mayes as President and CEO

High number of new and inexperienced directors

Field Trip Health&nbsp; GAAP EPS of -C$0.09

Field Trip Health Ltd., Annual General Meeting, Sep 29, 2022

Field Trip Health Ltd. completed the Split-Off of Field Trip Health & Wellness Ltd.

Field Trip Health Ltd. to Report Q1, 2023 Results on Aug 15, 2022

Field Trip Health Ltd. Announces First Successful Dosings in the Phase 1 Clinical Study Entitled A Double-Blind

Field Trip Health receives final court approval for clinics business spin-out

Field Trip Health Ltd. to Report Q4, 2022 Results on Jun 29, 2022

High number of new directors

Field Trip Health Ltd. Receives U.S. Patent Covering Novel Psychedelic Molecule FT-104

High number of new and inexperienced directors

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Field Trip Health Ltd. to Report Q3, 2022 Results on Feb 15, 2022

Field Trip Receives Notice of Allowance for US Patent Application Covering FT-104 (Isoprocin Glutarate), its Novel Psychedelic Molecule in Development

Field Trip Launches Site Management Organization Services

Second quarter 2022 earnings released: CA$0.23 loss per share (vs CA$0.16 loss in 2Q 2021)

Less than half of directors are independent

Field Trip Health Ltd. to Pursue Treatment Resistant Depression and Postpartum Depression as Indications for FT-104

Less than half of directors are independent

First quarter 2022 earnings released: CA$0.22 loss per share (vs CA$1.69 loss in 1Q 2021)

Less than half of directors are independent

Field Trip Health Ltd. Announces Completion of DMPK Studies, Engineering Batch for FT-104, Its Novel Psychedelic Compound

Field Trip Health Ltd. has completed a Follow-on Equity Offering in the amount of CAD 82.875 million.

Field Trip Health Ltd. to Report Q3, 2021 Results on Feb 16, 2021

Field Trip Health Ltd. Announces Participation in a Maps-Sponsored Multi-Site Study of Mdma-Assisted Therapy to Treat Eating Disorders

Field Trip Health Ltd. has completed a Composite Units Offering in the amount of CAD 17.406 million.

Field Trip Health Ltd. to Report Q2, 2021 Results on Nov 30, 2020

Field Trip Health Ltd. and Whoop Announces Partnership to Measure Effect of Psychedelic Therapies on Physiology and Mental Health

CEO

Tenure

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age

Field Trip Health GAAP EPS of -C$0.09